FREQ Key Statistics, Chart & Performance
The current stock price of FREQ is 0.2996 USD. In the past month the price decreased by -0.1%. In the past year, price decreased by -87.52%.
FREQ Latest News, Press Relases and Analysis
FREQ Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About FREQ
Company Profile
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person’s innate regenerative potential to restore function. The company is headquartered in Lexington, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2019-10-03. The Company, using its progenitor cell activation (PCA) platform, is developing its lead product candidate, FX-322, for the treatment of sensorineural hearing loss (SNHL). FX-322 is designed to treat the underlying cause of SNHL by regenerating hair cells through activation of progenitor cells already present in the cochlea. The firm is also conducting Phase IIb study for the product FX-322. The Company’s SNHL investigational therapeutic program, FX-345, is designed to achieve broader exposure through the cochlea. The Company’s progenitor cell activation (PCA) uses small molecules to activate progenitor cells within the body to create functional tissue.
Company Info
FREQUENCY THERAPEUTICS INC
75 Hayden Avenue, Suite 300
Lexington MASSACHUSETTS 01801 US
CEO: David L. Lucchino
Employees: 48
Phone: 17813154600.0
FREQUENCY THERAPEUTICS INC / FREQ FAQ
What does FREQUENCY THERAPEUTICS INC do?
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person’s innate regenerative potential to restore function. The company is headquartered in Lexington, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2019-10-03. The Company, using its progenitor cell activation (PCA) platform, is developing its lead product candidate, FX-322, for the treatment of sensorineural hearing loss (SNHL). FX-322 is designed to treat the underlying cause of SNHL by regenerating hair cells through activation of progenitor cells already present in the cochlea. The firm is also conducting Phase IIb study for the product FX-322. The Company’s SNHL investigational therapeutic program, FX-345, is designed to achieve broader exposure through the cochlea. The Company’s progenitor cell activation (PCA) uses small molecules to activate progenitor cells within the body to create functional tissue.
Can you provide the latest stock price for FREQUENCY THERAPEUTICS INC?
The current stock price of FREQ is 0.2996 USD. The price increased by 5.94% in the last trading session.
Does FREQUENCY THERAPEUTICS INC pay dividends?
FREQ does not pay a dividend.
What is the ChartMill technical and fundamental rating of FREQ stock?
FREQ has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for FREQ stock?
FREQUENCY THERAPEUTICS INC (FREQ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.2).
What is the market capitalization of FREQ stock?
FREQUENCY THERAPEUTICS INC (FREQ) has a market capitalization of 11.06M USD. This makes FREQ a Nano Cap stock.
FREQ Technical Analysis
FREQ Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FREQ. FREQ scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
FREQ Financial Highlights
Over the last trailing twelve months FREQ reported a non-GAAP Earnings per Share(EPS) of -2.2. The EPS increased by 13.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.59% | ||
| ROE | -145.99% | ||
| Debt/Equity | 0 |
FREQ Forecast & Estimates
6 analysts have analysed FREQ and the average price target is 0.51 USD. This implies a price increase of 70.23% is expected in the next year compared to the current price of 0.2996.